1. |
Terkeltaub R. Update on gout: new therapeutic strategies and options. Nat Rev Rheumatol, 2010, 6(1): 30-38.
|
2. |
Burns CM, Wortmann RL. Gout therapeutics: new drugs for an old disease. Lancet, 2011, 377(9760): 165-177.
|
3. |
杨瑞青, 肖镇. 痛风的诊治现状及进展. 中华临床医师杂志(电子版), 2016, 10(4): 550-553.
|
4. |
中华医学会风湿病学分会. 2016中国痛风诊疗指南. 中华内科杂志, 2016, 55(11): 892-899.
|
5. |
Zhang W, Doherty M, Bardin T, et al. EULAR evidence based recommendations for gout. Part Ⅱ: Management Report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis, 2006, 65: 1312-1324.
|
6. |
Goutsias J. A hidden Markov model for transcriptional regulation in single cells. IEEE/ACM Trans Comput Biol Bioinform, 2006, 3(1): 57-71.
|
7. |
Goutsias J. Classical versus stochastic kinetics modeling of biochemical reaction systems. Biophys J, 2007, 92(7): 2350-2365.
|
8. |
Jansen TL. Treat to target in gout by combining two modes of action. Rheumatology (Oxford), 2014, 53(12): 2131-2133.
|
9. |
Cattermole GN, Man CY, Cheng CH, et al. Oral prednisolone is more cost-effective than oral indomethacin for treating patients with acute gout-like arthritis. Eur J Emerg Med, 2009, 16(5): 261-266.
|
10. |
Huang X, Du H, Gu J, et al. An allopurinol-controlled, multicenter, randomized, double-blind, parallel between-group, comparative study of febuxostat in Chinese patients with gout and hyperuricemia. Int J Rheum Dis, 2014, 17(6): 679-686.
|
11. |
Xu S, Liu X, Ming J, et al. A phase 3, multicenter, randomized, allopurinol-controlled study assessing the safety and efficacy of oral febuxostat in Chinese gout patients with hyperuricemia. Int J Rheum Dis, 2015, 18(6): 669-678.
|
12. |
焦洋, 方卫纲, 曾学军. 别嘌醇及非布司他治疗中国痛风患者的成本效果. 中华临床免疫和变态反应杂志, 2016, 10(4): 334-339.
|
13. |
Khanna PP, Nuki G, Bardin T, et al. Tophi and frequent gout flares are associated with impairments to quality of life, productivity, and increased healthcare resource use: Results from a cross-sectional survey. Health Qual Life Outcomes, 2012, 10: 117.
|
14. |
Beard SM, von Scheele BG, Nuki G, et al. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ, 2014, 15(5): 453-463.
|
15. |
Gandhi PK, Gentry WM, Ma Q, et al. Cost-effectiveness analysis of allopurinol versus febuxostat in chronic gout patients: a U.S. payer perspective. J Manag Care Spec Pharm, 2015, 21(2): 165-175.
|
16. |
Perez-Ruiz F, Díaz-Torné C, Carcedo D. Cost-effectiveness analysis of febuxostat in patients with gout in Spain. J Med Econ, 2016, 19(6): 604-610.
|